Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
You did a dummy sell of 230k shares?! That’s scary.
Now able to get a quote again c156p
If you’re looking to buy via HL, you may want to try phoning them instead and saying that no quote is available online (hopefully they won’t charge you extra that way). Haven’t been able to get a quote via their app for over an hour...
His cousin George W Hippo told him about ACTIV-2 and he diversified.
I reckon George the Hippo is getting his A380 to attend President Elect Biden’s inauguration. What better time to announce promising new treatments for Covid than when you’ve just taken office?
Think it must be - he says “nebuliser interferon beta”. Great find dafad!
Press release just out from UCLA about adding two monoclonal antibodies to ACTIV-2 mentions that “inhaled agents” are being considered for inclusion in the trial:
“ ACTIV-2 has progressed on an unprecedented timeline. The ACTG received approval to develop an adaptive master platform trial for outpatients in May 2020 and enrolled the first participant less than 15 weeks later. Following intensive efforts to set up outpatient treatment sites, there are now 88 active U.S. sites, which are enrolling briskly. Thus far, ACTIV-2 has completed a phase 2 study of bamlanivimab (also a monoclonal antibody) and is evaluating several additional agents for potential inclusion (infusions, intramuscular injections, inhaled agents, and oral agents).”
https://www.newswise.com/coronavirus/actg-adds-new-agent-to-activ-2-trial-investigating-early-covid-19-treatments/?article_id=744057
Hi,
I don’t know if this has already been posted, but this article suggests that SARS-CoV-2 (COVID-19) is more susceptible to type I interferon than the original SARS-CoV virus, https://jvi.asm.org/content/94/23/e01410-20
It was a lab study and pre treatment was with interferon alpha but it’s worth a read I think (though don’t understand large sections of it).
“ In this report, we evaluate type I interferon (IFN-I) sensitivity of SARS-CoV-2 relative to the original SARS-CoV. Our results indicate that while SARS-CoV-2 maintains similar viral replication to SARS-CoV, the novel CoV is much more sensitive to IFN-I. In Vero E6 and in Calu3 cells, SARS-CoV-2 is substantially attenuated in the context of IFN-I pretreatment, whereas SARS-CoV is not.
...
The increased sensitivity of SARS-CoV-2 suggests utility in treatment using IFN-I. While IFN-I has been used in response to chronic viral infection (46), previous examination of SARS-CoV cases found inconclusive effects for IFN-I treatment (47). However, the findings from the SARS-CoV outbreak were complicated by combination therapy of IFN-I with other treatments, including ribavirin/steroids and lack of a regimented protocol. While IFN-I has been utilized to treat MERS-CoV-infected patients, no conclusive data yet exist to determine efficacy (48). However, in vivo studies with MERS-CoV have found that early induction with IFN-I can be protective in mice (49); importantly, the same study found that late IFN-I activation can be detrimental for MERS-CoV disease (49). Similarly, early reports have described treatments using IFN-I in combination for SARS-CoV-2 infection, though the efficacy of these treatments and the parameters of their use are not known (50). Overall, sensitivity data suggest that IFN-I treatment may have utility for treating SARS-CoV-2 if the appropriate parameters can be determined. In addition, use of type III IFN, which is predicted to have utility in the respiratory tract, could offer another means for effective treatment for SARS-CoV-2.”
Anyway, I’m off for a beer - happy New Year all!!
An article entitled "Type I interferon: From innate response to treatment for COVID-19" was published a couple of days ago and is available at https://onlinelibrary.wiley.com/doi/full/10.1002/ped4.12226
Some of it seems quite positive, and it mentions the phase 2 trial of SNG001 at the end of section 8 on nebulised interferon:
"8 Nebulized IFN treatment for COVID-19
IFN-I has been widely prescribed for various virus infections, including new virus pathogens. Clinical evidence of the antiviral effects of IFN treatment can usually be extrapolated to apply to phylogenetically closely related viruses. A randomized, double-blind, placebo-controlled, multicenter clinical study of aerosolized IFN-a1b inhalation in patients with adult viral pneumonia, including some patients with coronavirus, showed that the clinical symptoms of expectoration, lung rales, and respiratory rate were significantly improved, especially on days 5–7 after treatment, and the clinical symptoms improved significantly from 66% to 77% on the 7th day. This study supports the option for the emergency use of IFN-a to treat the COVID-19 pandemic. IFN-a aerosol inhalation was recommended as the first antiviral treatment of COVID-19 in the “Diagnosis and treatment protocol for COVID-19 patients” released by the National Health Commission of the People’s Republic of China, and in the recommendations for the treatment of children with COVID-19. Nebulized IFN-a2b, with or without Arbidol treatment, significantly reduced the duration of detectable SARS-CoV-2 virus in the upper respiratory tract and the duration of elevated blood levels of the inflammatory markers interleukin-6 and C-reactive protein. Nebulized IFN-a2b treatment could quickly reduce SARS-CoV-2 carriage. Liu et al reported that nebulized IFN-a2b, combined with low-dose systemic corticosteroids and lopinavir/ritonavir, contributed to the zero mortality rate in COVID-19 patients. Nebulized IFN was also shown to decrease mortality in COVID-19 patients in other studies. Fu et al showed that nebulized IFN-k plus trefoil factor 2 (TFF2) was associated with clinical improvement in COVID-19 patients and their consequent early discharge from hospital. A study involving about 100 COVID-19 patients (NCT04385095) reported that nebulized IFN-ß1a might be highly effective, with a 79% lower risk of developing severe disease."
Now 4th most viewed share on HL today, just above Tesla https://www.hl.co.uk/shares
Looking forward to this afternoon...
@Skeletor, i think Synairgen/Parexel are putting everything into setting up the global P3 trial and getting it right. This is the culmination of over a decade’s work for the company, and it’s their best opportunity to find out if SNG001 works as a broad spectrum anti-viral, including against COVID.
The start of the P3 trial hasn’t been announced but we know that it was approved by the MHRA on 6 November, https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-004743-83/GB
To complete a global P3 trial, go through peer review and, all being well, get SNG001 into production within 6 months would be an amazing accomplishment for a small company. The fact that they are looking for people with regulatory experience, including US regulatory experience, has to be a positive sign.
If Synairgen’s journey has a soundtrack, I reckon this is what RM is listening to with his shreddies: https://youtu.be/_Yhyp-_hX2s
Ghia, thanks - just looked at the jobs section at https://www.synairgen.com/contact-us/employment-opportunities/ and it has some very interesting bits:
“ To meet the demands if clinical studies are successful, we are working with a second drug substance supplier. Drug substance from this manufacturer will be used in commercial manufacture. The intention is to be able to supply the market in the middle of next year.”
As well as the need to:
“ Understand the regulatory framework in the EU, US and ROW for manufacturing and commercial launch”
But this pretty much sums it up:
“We are trying to get a drug that could save lives to the market as soon as possible.”
Great news CW - all the best to you parents for their continued recovery!
According to HL looks like there was a spike just before close?
Big, I did read it. You ended your post by saying:
“ RM should be repeating the same mantra day in day out - "Sales, Sales, Sales, Sales!" Not data, not research, not future possibilities, but hard Sales bringing in the cash.”
There’s no way for Synairgen (or anyone else) to sell a P2 trial stage drug apart from via a MAP or if an EUA is granted so you’re asking them to do the impossible.
How is Synairgen meant to sell, sell, sell sng001 when it has completed P2 but not yet started P3?! There is the MAP but not aware of any other routes.
Having been sitting on a big (paper) gain at one stage, and now sitting on a small (paper) loss, I can understand your frustration Big. However Synairgen realised they can’t do the P3 trial across 20 countries themselves, so they have Parexel running it for them. I think what Sunairgen has accomplished in the last 9 months is immense for a small company, particularly since SNG001 was one of the original drugs to be tested on the RECOVERY trial but was dropped because of concerns about supply. The placing has sorted that out too, and it now has an agreement with Akron.
This place gets a bit febrile at times - if you’re really thinking of selling, hope it works out for you, but hoping you and the other LTHs will stick around for the P3 results like I’ve decided to do. It’s only money ;o)
Big, why the change of heart? There's good reason to think that the P3 trial is about to start and, as painful as the placing has turned out to be, it funded the trial. The P3 trial means we're going to know if SNG001 works in a matter of months.
Hope your parents are better soon CW.
Interesting, might also explain attack of the trolls yesterday if word has got out. Thanks @cityttrader!